Vermillion Granted US Patent Supporting Vasclir Diagnostic; Begins Intended-Use Study for Test | GenomeWeb

Vermillion announced this week it has been granted a US patent allowing it to use B2-microglobulin as a biomarker for its peripheral artery disease diagnostic Vasclir and that it has begun an intended-use population study for the test.

The patent, number 7,867,719, covers "biomarker combinations that include B2-microglobulin for the diagnosis and management of peripheral artery disease and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay," the company said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: transcriptional map of human embryo development, circadian clock genes in acute myeloid leukemia, and more.

The US National Academy of Sciences has announced 84 new members and 21 foreign associates.

The users of file-sharing site Sci-Hub work all around the globe where research is going on, Science's John Bohannon reports.

Researchers link obesity in Labrador retrievers to a deletion in their POMC gene.